Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2012-04-28 Notice of Dividend Amou…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Dividend notification FR.pdf
Notice of Dividend Amount Classification · 99% confidence The document is titled "AVIS AUX ACTIONNAIRES" (Notice to Shareholders) and specifically concerns the "ACTION UCB DIVIDENDE 2011". It details the amount of the dividend (0.75 EUR net) and the payment date (May 3, 2012). This content directly relates to the announcement of dividend amounts and payment details, matching the definition for 'Notice of Dividend Amount'. The document is very short (431 characters), but its explicit subject matter overrides the general RPA/RNS fallback, as DIV is a specific category for dividend notices.
2012-04-28 French
Dividend notification NL.pdf
Notice of Dividend Amount Classification · 99% confidence The document is very short (463 characters) and explicitly titled 'BERICHT AAN DE AANDEELHOUDERS' (Announcement to Shareholders) concerning 'UCB AANDEEL DIVIDEND 2011' (UCB Share Dividend 2011). It details the dividend amount (0.75 EUR net) and the payment date (May 3, 2012). This directly corresponds to the definition of a Notice of Dividend Amount.
2012-04-28 Dutch
UCB 3m Interim report UK.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'UCB Interim Report – first three months 2012'. It provides detailed financial performance data, including revenue figures (EUR 877 million), recurring EBITDA, and net profit performance for the specified period. It also includes detailed operational updates on R&D and product sales. Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). Q1 2012
2012-04-26 English
UCB 3m Interim report FR.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for UCB covering the first three months of 2012. It includes detailed financial performance data (revenue of EUR 877 million, EBITDA, and net profit), analysis of product sales (Cimzia, Vimpat, Neupro, Keppra), R&D updates, and financial outlook for the full year. It is not merely an announcement of a report, but the report itself, containing substantive financial data and management analysis for an interim period. Q1 2012
2012-04-26 French
UCB 3m Interim report NL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly report ('tussentijds verslag') for the first three months of 2012. It contains substantive financial data, including revenue figures for specific products (Cimzia, Vimpat, Neupro, Keppra), total revenue, EBITDA, and net profit projections. It is not merely an announcement of a report, but the report itself, providing detailed financial analysis and operational updates. Therefore, it is classified as an Interim/Quarterly Report. Q1 2012
2012-04-26 Dutch
Cimzia® (certolizumab pegol) shows positive top-line phase 3 results in axial spondyloarthritis and ankylosing spondylitis
Legal Proceedings Report Classification · 99% confidence The document is a press release dated April 16, 2012, announcing positive top-line Phase 3 results for the drug Cimzia® in treating axial spondyloarthritis. It details the study design, efficacy endpoints (ASAS20), safety profile (adverse events, serious infections, malignancies), and provides extensive background information on the disease and the drug. This content structure—announcing clinical trial results and providing context—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical news. Since it focuses specifically on the announcement of clinical trial results and is not a full, comprehensive financial report (like a 10-K or IR), nor is it a transcript (CT) or a formal investor presentation (IP), the most fitting category is Earnings Release (ER), as clinical trial results often accompany or substitute for quarterly earnings announcements in the pharmaceutical sector, or it could be classified as a Regulatory Filing (RNS) if it were a mandatory filing. Given the format is a news announcement of clinical data, ER is a strong fit, but since it's not explicitly tied to a quarterly reporting period summary, and it's a specific clinical update, it functions as a major corporate announcement. However, looking at the definitions, it is not a 'Call Transcript' (CT), 'Investor Presentation' (IP), or 'Interim Report' (IR). It is a direct announcement of results. In the context of financial reporting, major clinical trial updates are often released via press release, which sometimes falls under ER if it's near a reporting period, or RNS if it's a general regulatory announcement. Since it contains detailed clinical data and safety warnings, it is more substantial than a simple 'Report Publication Announcement' (RPA). Given the options, and recognizing this as a major corporate news announcement detailing clinical progress, it aligns best with the function of an Earnings Release (ER) which communicates key performance indicators (in this case, clinical success) to the market, or RNS as a general regulatory announcement. Since it is a press release announcing a major corporate development (positive trial results), and not a formal financial statement, RNS (Regulatory Filings/General Announcement) is the safest general classification for non-standard financial disclosures, although ER is plausible if this release accompanied Q1 results. Given the lack of explicit financial metrics (revenue, EPS), RNS is more appropriate as a catch-all for significant, non-standard corporate news releases.
2012-04-16 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.